Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 77

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 77
---
 commercially reasonable terms in the 90 days after acceptance of the filing of an NDA by the U. S. Food and
Drug Administration (the “ FDA”). If the Company does not exercise the option, it would be required to make additional quarterly
payments, as disclosed in note 16, until the first commercial sale of the product.

   1      Number of ADSs have been adjusted to reflect the ADS ratio change  
          on 4 October 2024                                                  
 ─────────────────────────────────────────────────────────────────────────────

12 Subsidiaries

The subsidiaries of the Company, all
of which are 100% owned as at 31 December 2024, either directly or through subsidiaries where indicated, and have been included in these
financial statements in accordance with the details set out in the basis of preparation and basis of consolidation note 1, are as follows:

  Schedule of subsidiaries                                                                                                                                                                    
  Name                                         Registered                                                                                                       Nature of            Notes    
  Biodexa Australia PTY Limited                c/o Prime Accounting & Business Advisory, HWT Towel Level 17, 40 City Road, Southbank, VIC, 3006, Australia      Trading company               
  Biodexa Limited                              1 Caspian Point, Caspian Way, Cardiff,                                                                           Trading company               
  Biodexa Pharmaceuticals (Wales) Limited      1 Caspian Point, Caspian Way, Cardiff,                                                                           Trading company               
  Haaland UK Limited                           1 Caspian Point, Caspian Way,                                                                                    Dormant                       
  PharMida AG                                  c/o Kellerhals, Hirschgässlein 11, 4051 Basel, Switzerland                                                       Dormant              (a) (b)  

Notes:

  (a)      Wholly owned subsidiary of Biodexa Limited.  

  (b)      PharMida AG became dormant in January 2016  
 ───────────────────────────────────────────────────────

13 Trade
and other receivables

  Schedule of trade and other receivables                                 
  Trade receivables                               11      –          329  
  Prepayments                                  6,426      355        376  
  Other receivables                              131      282        301  
  Total trade and other receivables            6,568      637      1,006  
  Less: non-current portion                        –      –            –  
  Current portion                              6,568